Skip to content
zameds

Afatinib (Giotrif)

Afatinib

Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale

S4

Registration

Applicant
Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale
Registrations
3
Schedule source
Consolidated Schedules 06 July 2026

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Giotrif 20 MG

EACH TABLET CONTAINS: AFATINIB 20,0 mg

20 mg47101647/26/1016RegisteredS4None
Giotrif 30 MG

EACH TABLET CONTAINS: AFATINIB 30,0 mg

30 mg47101747/26/1017RegisteredS4None
Giotrif 40 MG

EACH TABLET CONTAINS: AFATINIB 40,0 mg

40 mg47101847/26/1018RegisteredS4None

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Afatinib

  • S4: Afatinib

    Consolidated Schedules 06 July 2026, line 5150

Pharmacological class: Cytostatic agents (class 26)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C24H25ClFN5O3485.90 g/mol

(E)-N-[4-(3-Chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide

Drag to rotate. Structure from PubChem CID 10184653.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles